{
  "docId": "019de514-833c-7520-a4a9-200b68fbb681",
  "docSlug": "d869e39fe11534a9d64784c9e4f475f2",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 47 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 47,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "revenue_buildup",
  "function": "decompose_segments",
  "density": "dense",
  "nDataPoints": 48,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-833c-7520-a4a9-200b68fbb681/12",
  "deckHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681",
  "deckJsonHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681.json",
  "deckAnchorHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.029,
        "w": 0.104,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "image",
      "text": "BAUSCH+ LOMB",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ac933b5-30fa-4d88-8e75-77dd3e084d80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.064,
        "w": 0.702,
        "x": 0.155,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n3. On a proforma basis after giving effect to the IPO.\n4. Organic revenue growth/change, a non-GAAP measure, is defined as change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bbfeec86-3fc1-4140-a506-13c27386a307",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.706,
        "w": 0.855,
        "x": 0.073,
        "y": 0.165
      },
      "kind": "table",
      "text": "Bausch + Lomb 3Q22 3Q21 Reported Change Constant Currency2 Organic Change 2,4 Vision Care Revenue $598M $605M (1%) 4% 4% Surgical Revenue $172M $173M (1%) 7% 8% Ophthalmic Pharmaceuticals Revenue $172M $171M 1% 5% 5% Total Revenue $942M $949M (1%) 5% 5% Gross Profit $510M $505M 1% 6% Gross Margin 54.1% 53.2% 90 bps R&D $77M $63M (22%) (25%) R&D percent of Revenues 8.2% 6.6% SG&A $381M $348M (9%) (16%) SG&A percent of Revenues 40.4% 36.7% Operating Income $46M $94M (51%) (47%) Depreciation $34M $26M 31% 38% Stock Based Compensation $18M $16M 13% 13% Net (Loss) Income Attributable to Bausch + Lomb ($18M) $60M (130%) (167%) Net Income Margin (1.9%) 6.3% EPS3 Attributable to Bausch + Lomb ($0.05) $0.17",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d91aa70-bc1a-41d3-b865-98aea0a54803",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.027,
        "w": 0.409,
        "x": 0.047,
        "y": 0.047
      },
      "kind": "title",
      "text": "Total Bausch + Lomb P&L¹ (GAAP)",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abfed607-da3d-4884-abfb-8cd6528f4564",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "821d9c79-2849-4ad4-8577-266e30ea3e83",
      "evidence": "Bausch + Lomb 3Q22 3Q21 Reported Change Constant Currency2 Organic Change 2,4 Vision Care Revenue $598M $605M (1%) 4% 4% Surgical Revenue $172M $173M (1%) 7% 8% Ophthalmic Pharmaceuticals Revenue $172M $171M",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 10,
      "beatId": "c497fb1e-88d6-4d42-be4d-16858604e6da",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck provides a revenue bridge, P&L, and guidance for FY 2022.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}